Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

empagliflozin / Linagliptin

Known as: EMPAGLIFLOZIN/LINAGLIPTIN, linagliptin and empagliflozin 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Recent data have indicated the emerging role of glomerular autophagy in diabetic kidney disease. We aimed to assess the effect of… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2018
2018
Aims This double‐blind, randomized, placebo‐controlled trial (http://clinicaltrials.gov NCT02453555) evaluated the efficacy and… Expand
  • table 1
  • figure 1
  • figure 3
  • table 2
Is this relevant?
Review
2017
Review
2017
ABSTRACT Introduction: Type 2 diabetes mellitus (T2DM) is typically progressive, with sequential addition of therapies often… Expand
Is this relevant?
Review
2016
Review
2016
Glyxambi® (empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2… Expand
Is this relevant?
Review
2016
Review
2016
IntroductionThe duration of uncontrolled type 2 diabetes mellitus (T2DM) can adversely impact small and large vessels, eventually… Expand
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BackgroundSodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyperglycemia by… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2016
Review
2016
  • André Scheen
  • Expert opinion on drug metabolism & toxicology
  • 2016
  • Corpus ID: 3916872
ABSTRACT Introduction: Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of… Expand
Is this relevant?
2016
2016
Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
OBJECTIVE To evaluate the efficacy and safety of combinations of empagliflozin/linagliptin as second-line therapy in subjects… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2015
Review
2015
  • V. Woo
  • International journal of clinical practice
  • 2015
  • Corpus ID: 15215613
Summary Background The availability of a dual sodium glucose co‐transporter 2/dipeptidyl peptidase‐4 inhibitor combination in a… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?